Stempoint Capital’s Fate Therapeutics FATE Stock Holding History

Stempoint Capital’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-898,196	Closed	-$3.36M	–	74
2023 Q4	$3.36M	Buy	+898,196	New	+$2.12M	0.9%	39

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stempoint Capital's FATE Position: Q1 2024 in Review

Stempoint Capital sold out of Fate Therapeutics (FATE) in Q1 2024, closing a stake of 898,196 shares — an estimated $3.36M sold.

Stempoint Capital first reported a position in FATE in Q4 2023 and held it in 1 quarter. The position peaked at $3.36M in Q4 2023. 167 funds tracked by Wall St. Rank hold FATE as of Q1 2024.

Stempoint Capital reported no remaining Fate Therapeutics position as of Q1 2024 after selling out during the quarter.
Stempoint Capital sold 898,196 Fate Therapeutics shares in Q1 2024, an estimated $3.36M.
Stempoint Capital first reported a position in Fate Therapeutics in Q4 2023 and held it in 1 quarter.
Stempoint Capital's Fate Therapeutics position peaked at $3.36M in Q4 2023.
167 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2024.

Based on Stempoint Capital's 13F filing for Q1 2024, filed 14 May 2024.